Onyx Pharmaceuticals Articles
US and European hema-oncologists views therapies for relapsed/refractory multiple myeloma
15 May 2013
FDA expands use of Bayer and Onyx' Stivarga for advanced GIST
26 February 2013
AVEO/Astellas' kidney cancer drug tivozanib fails to beat Nexavar
14 February 2013
News briefs: Bayer's Stivarga and AstraZeneca's Faslodex
30 October 2012
Bayer files NDA for regorafenib for the treatment of GIST
31 August 2012
Batch of mixed opinions from FDA advisory panels
21 June 2012
Senior appointments as Sanofi and Onyx
5 March 2012
Bayer’s Xarelto OKed in Japan; promising regorafenib data
19 January 2012
Onyx joins with MMRF to advance MM targeted therapies
15 December 2011
Onyx falls as FDA says no priority review for cancer drug
13 December 2011
Onyx Pharma files NDA for multiple myeloma drug carfilzomib
29 September 2011
Executive changes at Onyx Pharma and XOMA
2 September 2011
Bayer/Onyx’s Nexavar disappoints as first-line advanced NSCLC therapy, failing to meet goals in Ph III study
14 June 2010
Pfizer discontinues Ph III trial of Sutent in advanced liver cancer as it fails versus Bayer’s Nexavar
26 April 2010
Showing 1-29 of 29 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
